HCW Biologics
NASDAQ: HCWBMiramar, US · Founded 2018 · Delaware corporation · 32 employees on LinkedIn · 1 known investors
HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics as first-in-class immunotherapies for autoimmune diseases, cancer, and senescence-associated dysplasia. It uses proprietary drug discovery platforms to create multi-specific cytokines, targeted immune checkpoint inhibitors, and immune-cell engagers, with lead candidates in commercial and clinical stages.
Founders & leadership
HCW Biologics was founded in 2018 by Hing C Wong, Hing C. Wong, and Hing W..
HC
Hing C WongCo-founder
HC
Hing C. WongFounder & CEO
HW
Hing W.inFounder & CEOHing W. has more than 15 years of experience adjusting and consulting on large-loss insurance claims for policyholders, and previously co-founded and sold his stake in a private adjusting firm. A finance graduate, he also consults for tech startups and works on real estate, hospitality, and property management ventures, with current projects including the claims-adjusting AI software Claim, Inc., Progress Coffee, and Cabana Club.
LF
Lee FlowersExecutive
RB
Rebecca ByamExecutive
PR
Peter RhodeExecutive
PS
Peter SunNamed on SEC filing
NV
Nicole ValdiviesoNamed on SEC filing
Board
FM
GW
Gary WinerBoard director
RS
Rick S. GreeneBoard director
LM
Lisa M. GilesBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$21.2M disclosed across 5 rounds · 2020–2026
▶$1.6MraisedAug 2026 · 4 investors · BiotechnologyRule 506(b)
▶$1.6MraisedAug 2026 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Hing C. WongExecutive Officer, Director
- Rebecca ByamExecutive Officer
- Peter RhodeExecutive Officer
- Scott T. GarrettDirector
- Rick S. GreeneDirector
- Lisa M. GilesDirector
- Lee FlowersExecutive Officer
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedJun 2026 · 7 investors · BiotechnologyRule 506(b)
▶$4MraisedJun 2026 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
- Scott T. GarrettDirector
- Lee FlowerExecutive Officer
- Peter RhodeExecutive Officer
- Lisa M. GilesDirector
- Hing C. WongExecutive Officer, Director
- Rick S. GreeneDirector
- Rebecca ByamExecutive Officer
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.9MraisedDec 2024 · 1 investors · BiotechnologyRule 506(b)
▶$6.9MraisedDec 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lee FlowersExecutive Officer
- Gary WinerDirector
- Rick S. GreeneDirector
- Rebecca ByamExecutive Officer
- Lisa M. GilesDirector
- Scott T. GarrettDirector
- Hing C WongExecutive Officer, Director
- Peter RhodeExecutive Officer
- Offering amount
- $6.9M
- Amount sold
- $6.9M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedFeb 2024 · 6 investors · BiotechnologyRule 506(b)
▶$2.5MraisedFeb 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Hing C. WongExecutive Officer, Director
- Rick S. GreeneDirector
- Peter RhodeExecutive Officer
- Lisa M. GilesDirector
- Gary WinerDirector
- Scott T. GarrettDirector
- Lee FlowersExecutive Officer
- Rebecca ByamExecutive Officer
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.2MraisedOct 2020 · 9 investors · BiotechnologyRule 506(b)
▶$6.2MraisedOct 2020 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Hing C WongExecutive Officer, Director
- Peter SunDirector
- Fred M. MiddletonDirector
- Rebecca ByamExecutive Officer
- Peter RhodeExecutive Officer
- Nicole ValdiviesoExecutive Officer
- Offering amount
- $16M
- Amount sold
- $6.2M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlap
StockTwits16 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Simply Wall St14 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
Robinhood14 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingView14 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Seeking Alpha13 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Kraken10 shared keywordsKraken 360 Investments provides capital and launch infrastructure to blockchain protocols in pre-token and early post-token phases, offering custody, staking, treasury, and liquidity services alongside fundraising support.
Interactive Strength Acquires Ergatta9 shared keywordsFidelity provides brokerage and investing services for individual retail investors, including commission-free online trading of US stocks and ETFs and fractional share purchases starting at $1. It positions itself as a personal finance and investment provider serving customers pursuing long-term financial goals.
Companies competing with HCW Biologics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
HCW Biologics Raises $1.6 Million in Private Placement; Units Priced at $2.585 — TradingView Newstradingview.com · Jul 2026
HCW Biologics Announces Pricing of $1.6 Million Private Placement Offering | Quiver Quantitativequiverquant.com · Jul 2026Frequently asked questions
- What does HCW Biologics do?
- HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics as first-in-class immunotherapies for autoimmune diseases, cancer, and senescence-associated dysplasia. It uses proprietary drug discovery platforms to create multi-specific cytokines, targeted immune checkpoint inhibitors, and immune-cell engagers, with lead candidates in commercial and clinical stages.
- Who founded HCW Biologics?
- HCW Biologics was founded by Hing C Wong, Hing C. Wong, Hing W. in 2018.
- Who are HCW Biologics's investors?
- HCW Biologics's investors include Sanderling Ventures.
- How much funding has HCW Biologics raised?
- HCW Biologics has disclosed $21.2M raised across 5 rounds.
- Where is HCW Biologics headquartered?
- HCW Biologics is headquartered in Miramar, US.